NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-OD-21-182 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-178 from the NIH Guide for Grants and Contracts
Notice NOT-NS-22-018 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-21-020 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this National Cancer Institute (NCI) R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences, Curriculum or Methods Development and Outreach. The NCIs mission is to conduct and support research, training, health information dissemination, and other programs with respect to cancer. This funding opportunity seeks to facilitate the education of students from diverse backgrounds underrepresented in biomedical research who will become knowledgeable about cancer, and available to focus on cancer later in their careers. With the aim of enhancing the pool of individuals from underrepresented backgrounds interested in pursuing a career in biomedical research via early intervention strategies, the NCI Youth Enjoy Science (YES) Program will support efforts to create and maintain an institutional program to engage grades 6-12 and/or undergraduate students from underrepresented populations in cutting edge cancer research experiences. The proposed institutional programs may also provide research experiences for the grade 6-12 teachers and undergraduate faculty members who serve underrepresented student populations. The specific goals are to inspire interest in biomedical sciences, help envision research as a career path, and strengthen practical research and career skills. In alignment with these goals, institutions may develop unique programs that capitalize on their research strengths and are responsive to their target populations.
Funding Opportunity PAR-21-317 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase (UH3) of up to five years. Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents. The UH3 phase will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stages 0/ I) through implementation and cost-effectiveness research (Stages IV/V).
Notice NOT-AI-21-076 from the NIH Guide for Grants and Contracts
Notice NOT-DE-21-012 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-110 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-057 from the NIH Guide for Grants and Contracts
Notice NOT-AG-21-058 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-320 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. This FOA is intended to support research education activities that enhance the knowledge of substance use and substance use disorder research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/health service providers, clinical researchers, or optimally a combination of the two. This mechanism may not be used to support non-research-related clinical training.
Funding Opportunity RFA-CA-21-057 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) solicits applications for Connecting Underrepresented Populations to Clinical Trials (CUSP2CT), a program that will implement and evaluate multilevel and culturally tailored outreach and education interventions with the primary goal of increasing referral and ultimately, accrual of underrepresented racial/ethnic (R/E) minority populations, to NCI-supported clinical trials (CTs) (National Clinical Trial Network (NCTN), NCI's Community Oncology Research Program (NCORP), and Experimental Therapeutics Clinical Trials Network (ETCTN)). The target population(s) should include individuals from underrepresented racial/ethnic (R/E) minority populations. Applicants should address cancer health disparities (CHD) through a network of local multidisciplinary and integrated partners that include community health educators (CHEs), lay health advisors (LHAs), community members, healthcare providers, and researchers working in coordination to educate and refer R/E minority populations to NCI-supported CTs, and increase awareness in providers about R/E minority participation in NCI clinical trials. This will require outreach and education multilevel interventions at the CT site, provider, and/or patient levels. The proposed interventions should be informed by relevant theories, frameworks, or models and guided by preliminary data and/or the sufficient infrastructure in place and expertise on the local contextual barriers and facilitators for increasing CT referral of R/E minority population. It is expected that U01 grantees will establish partnerships with the community, primary care providers, and other stakeholders to enhance identification of R/E minority referral barriers and facilitators to NCI-supported CTs. A companion funding opportunity (see U24 funding opportunity RFA-CA-21-058) will support a Data, Evaluation and Coordinating Center (DECC) that will provide experienced project
Funding Opportunity RFA-CA-21-058 from the NIH Guide for Grants and Contracts. The purpose of this solicitation is to fund a Data, Evaluation and Coordinating Center (DECC) that will support the data and evaluation activities and coordinate a learning collaborative related to the CUSP2CT program (companion RFA CA-21-057).
Funding Opportunity RFA-AA-21-015 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U54 applications for the planning and implementation of collaborative partnerships between Research Centers in Minority Institutions (RCMI) and institutions with extensive alcohol research programs, including NIAAA-funded alcohol research centers and consortia (ARC). RCMI are institutions that offer doctorate degrees in the health professions or in a health-related science and have a historical and current commitment to educating underrepresented students, and for institutions that deliver health care services, providing clinical services to medically underserved communities. ARC refers to institutions with extensive alcohol research programs including, but not limited to, NIAAA-funded alcohol research centers. The long-range goal of the collaborative partnership program between RCMI and ARC is to strengthen the alcohol research capacity, develop research expertise in biomedical and clinical fields to identify, characterize, and reduce adverse health effects due to alcohol use and misuse. This FOA aims to support RCMI to build alcohol research infrastructure and capacity and to enhance diversity in the biomedical workforce.
Funding Opportunity RFA-DK-21-022 from the NIH Guide for Grants and Contracts. The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) was established in July 2002 for the purpose of identifying genetic variation predisposing to Inflammatory Bowel Disease (IBD). Since its establishment and in collaboration with the International IBD Genetics Consortium, the NIDDK IBDGC has identified over 250 IBD susceptibility loci. However, for the great majority of these loci, the specific causal variants and effector genes have not yet been identified, and the biological mechanisms through which these variants influence IBD pathophysiology remain to be elucidated. The purpose of this FOA is to renew the IBDGC with a continued mission to characterize the genetic architecture of IBD and its sub-phenotypes, particularly in populations currently under-represented in IBD genomic studies, and to elucidate the biological mechanisms by which genetic variants influence IBD pathophysiology, phenotypes and outcomes, with the long-term goal of improving disease course prediction and treatment. The Genetic Research Centers (GRCs) of the IBDGC will serve as sites for enrollment of IBD patients, relatives and healthy controls, for laboratory-based studies on biological samples taken from these subjects, and for mechanistic studies of the variants identified and of the genes, proteins and pathways they impact. The Program Directors / Principal Investigators of the GRCs will serve as voting members of the Steering Committee of the IBDGC, which will be responsible for all operational decisions, which will be binding upon all members of the IBDGC.
Notice NOT-MH-21-310 from the NIH Guide for Grants and Contracts
Notice NOT-AI-21-077 from the NIH Guide for Grants and Contracts
Notice NOT-OH-21-014 from the NIH Guide for Grants and Contracts
Notice NOT-OH-21-013 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HG-21-036 from the NIH Guide for Grants and Contracts. The purpose of the Knockout Mouse Phenotyping Project (KOMP2) is to produce a comprehensive resource of null-mutant mice, and associated phenotype data, for the purpose of elucidating functional information for each protein-coding gene in the mammalian genome. This Funding Opportunity Announcement (FOA) solicits applications for production and phenotyping centers that will make maximum progress toward completion of KOMP2 in a final five-year project period. The specific objectives are to generate approximately 1,200 mutant mouse lines using CRISPR/Cas9 technology, perform a series of phenotyping assays, cryopreserve germplasm, and make mice and data readily available to the research community. This is a limited competition RFA. Only recipient organizations funded under (RFA-RM-15-017) are eligible to apply.